Pub Date : 2024-11-16DOI: 10.1016/j.prro.2024.11.003
Jennifer Y Wo, Jonathan B Ashman, Nishin A Bhadkamkar, Lisa Bradfield, Daniel T Chang, Nader Hanna, Maria Hawkins, Michael Holtz, Edward Kim, Patrick Kelly, Diane C Ling, Jeffrey R Olsen, Manisha Palta, Ann C Raldow, Erika Ruiz-Garcia, Arshin Sheybani, Karyn B Stitzenberg, Prajnan Das
Purpose: With the results of several recently published clinical trials, this guideline focused update provides evidence-based recommendations for the indications and dose-fractionation regimens for neoadjuvant radiation therapy (RT), optimal sequencing of RT and systemic therapy in the context of total neoadjuvant therapy (TNT), and considerations for selective omission of RT and surgery for rectal cancer.
Methods: The American Society for Radiation Oncology convened a multidisciplinary task force to update 3 key questions that focused on the role of RT for patients with operable rectal cancer. The key questions addressed (1) indications for neoadjuvant RT, (2) selection of neoadjuvant regimens, and (3) indications for consideration of a nonoperative management (NOM) or local excision approach after definitive/preoperative chemoradiation. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation.
Results: For patients with stage II-III rectal cancer, neoadjuvant RT was strongly recommended; however, among patients deemed at lower risk of locoregional recurrence, consideration of omission of neoadjuvant RT was conditionally recommended in favor of neoadjuvant chemotherapy with a favorable treatment response or upfront surgery. For patients with T3-T4 and node positive rectal cancer undergoing neoadjuvant RT, a TNT approach was strongly recommended. Among patients with higher risk of locoregional recurrence, TNT with chemotherapy before or after long-course chemoradiation was strongly recommended, whereas TNT with short-course RT followed by chemotherapy was conditionally recommended. For patients with rectal cancer for whom NOM is a priority, concurrent chemoradiation followed by consolidation chemotherapy was strongly recommended. Selection of RT dose-fractionation regimen, sequencing of therapies, and consideration of NOM should be determined by multidisciplinary consensus, and based on disease extent, disease location, patient preferences, and quality of life considerations.
Conclusions: The task force has proposed recommendations to inform best clinical practices on the use of RT for rectal cancer with strong emphasis on multidisciplinary care. Future studies should focus on further addressing optimal treatment regimens to allow for more personalized recommendations based on individual risk stratification and patient priorities regarding quality of life.
{"title":"Radiation Therapy for Rectal Cancer: An ASTRO Clinical Practice Guideline Focused Update.","authors":"Jennifer Y Wo, Jonathan B Ashman, Nishin A Bhadkamkar, Lisa Bradfield, Daniel T Chang, Nader Hanna, Maria Hawkins, Michael Holtz, Edward Kim, Patrick Kelly, Diane C Ling, Jeffrey R Olsen, Manisha Palta, Ann C Raldow, Erika Ruiz-Garcia, Arshin Sheybani, Karyn B Stitzenberg, Prajnan Das","doi":"10.1016/j.prro.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.prro.2024.11.003","url":null,"abstract":"<p><strong>Purpose: </strong>With the results of several recently published clinical trials, this guideline focused update provides evidence-based recommendations for the indications and dose-fractionation regimens for neoadjuvant radiation therapy (RT), optimal sequencing of RT and systemic therapy in the context of total neoadjuvant therapy (TNT), and considerations for selective omission of RT and surgery for rectal cancer.</p><p><strong>Methods: </strong>The American Society for Radiation Oncology convened a multidisciplinary task force to update 3 key questions that focused on the role of RT for patients with operable rectal cancer. The key questions addressed (1) indications for neoadjuvant RT, (2) selection of neoadjuvant regimens, and (3) indications for consideration of a nonoperative management (NOM) or local excision approach after definitive/preoperative chemoradiation. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for quality of evidence grading and strength of recommendation.</p><p><strong>Results: </strong>For patients with stage II-III rectal cancer, neoadjuvant RT was strongly recommended; however, among patients deemed at lower risk of locoregional recurrence, consideration of omission of neoadjuvant RT was conditionally recommended in favor of neoadjuvant chemotherapy with a favorable treatment response or upfront surgery. For patients with T3-T4 and node positive rectal cancer undergoing neoadjuvant RT, a TNT approach was strongly recommended. Among patients with higher risk of locoregional recurrence, TNT with chemotherapy before or after long-course chemoradiation was strongly recommended, whereas TNT with short-course RT followed by chemotherapy was conditionally recommended. For patients with rectal cancer for whom NOM is a priority, concurrent chemoradiation followed by consolidation chemotherapy was strongly recommended. Selection of RT dose-fractionation regimen, sequencing of therapies, and consideration of NOM should be determined by multidisciplinary consensus, and based on disease extent, disease location, patient preferences, and quality of life considerations.</p><p><strong>Conclusions: </strong>The task force has proposed recommendations to inform best clinical practices on the use of RT for rectal cancer with strong emphasis on multidisciplinary care. Future studies should focus on further addressing optimal treatment regimens to allow for more personalized recommendations based on individual risk stratification and patient priorities regarding quality of life.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-16DOI: 10.1016/j.prro.2024.08.012
Ambrosia Simmons, David Sher, Dr Dong Wook Nathan Kim, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Stephen Seiler, Sarah Neufeld, Maggie Stein, Kevin Albuquerque, Ann Spangler, John Heinzerling, Dan Garwood, Stella Stevenson, Chul Ahn, Chuxiong Ding, Robert D Timmerman, Asal Rahimi
Purpose: We report the financial toxicity and quality-of-life outcomes of our prospective phase 1 dose-escalation study of 5-fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer.
Materials and methods: Women with unifocal in situ or invasive epithelial histologies, clinical stages 0, I, or II with tumor size < 3 cm treated with lumpectomy were enrolled in our phase 1 5-fraction S-PBI dose-escalation trial. Our institutionally generated questionnaire on the "Patient Perspective Cost and Convenience of Care" and the EuroQol 5-Dimension 5-level questionnaire were administered to patients treated at follow-up.
Results: Between 2010 and 2015, 68 of the 75 patients who enrolled and completed treatment on trial completed at least some component of either the EuroQol 5-Dimension 5-level questionnaire or the "Patient Perspective Cost and Convenience of Care" questionnaire. Nearly all patients reported very high satisfaction with their treatment overall, particularly the shortened length of treatment. Over half of the patients reported some level of financial toxicity (FT) despite a significantly shortened treatment time. Patients who reported any FT were significantly younger than patients with no financial burden of treatment (means 59.2 and 63.7, respectively, P = .03). There was no difference in those who reported any level of FT based on patient race, ethnicity, marital, or employment status. This S-PBI regimen did not significantly affect quality of life over a 4-year follow-up.
Conclusions: These patient-reported outcomes suggest that the use of accelerated partial breast irradiation may offer low FT rates in breast cancer care, particularly for disadvantaged patient groups.
{"title":"Financial Toxicity and Quality-of-Life Outcomes on a Phase 1 5-fraction Stereotactic Partial Breast Irradiation Protocol for Early-Stage Breast Cancer.","authors":"Ambrosia Simmons, David Sher, Dr Dong Wook Nathan Kim, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Stephen Seiler, Sarah Neufeld, Maggie Stein, Kevin Albuquerque, Ann Spangler, John Heinzerling, Dan Garwood, Stella Stevenson, Chul Ahn, Chuxiong Ding, Robert D Timmerman, Asal Rahimi","doi":"10.1016/j.prro.2024.08.012","DOIUrl":"10.1016/j.prro.2024.08.012","url":null,"abstract":"<p><strong>Purpose: </strong>We report the financial toxicity and quality-of-life outcomes of our prospective phase 1 dose-escalation study of 5-fraction stereotactic partial breast irradiation (S-PBI) for early-stage breast cancer.</p><p><strong>Materials and methods: </strong>Women with unifocal in situ or invasive epithelial histologies, clinical stages 0, I, or II with tumor size < 3 cm treated with lumpectomy were enrolled in our phase 1 5-fraction S-PBI dose-escalation trial. Our institutionally generated questionnaire on the \"Patient Perspective Cost and Convenience of Care\" and the EuroQol 5-Dimension 5-level questionnaire were administered to patients treated at follow-up.</p><p><strong>Results: </strong>Between 2010 and 2015, 68 of the 75 patients who enrolled and completed treatment on trial completed at least some component of either the EuroQol 5-Dimension 5-level questionnaire or the \"Patient Perspective Cost and Convenience of Care\" questionnaire. Nearly all patients reported very high satisfaction with their treatment overall, particularly the shortened length of treatment. Over half of the patients reported some level of financial toxicity (FT) despite a significantly shortened treatment time. Patients who reported any FT were significantly younger than patients with no financial burden of treatment (means 59.2 and 63.7, respectively, P = .03). There was no difference in those who reported any level of FT based on patient race, ethnicity, marital, or employment status. This S-PBI regimen did not significantly affect quality of life over a 4-year follow-up.</p><p><strong>Conclusions: </strong>These patient-reported outcomes suggest that the use of accelerated partial breast irradiation may offer low FT rates in breast cancer care, particularly for disadvantaged patient groups.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142649685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-13DOI: 10.1016/j.prro.2024.10.015
Paul E Wallner, Michael L Steinberg
{"title":"Time to Slash SABR From Our Lexicon.","authors":"Paul E Wallner, Michael L Steinberg","doi":"10.1016/j.prro.2024.10.015","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.015","url":null,"abstract":"","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-13DOI: 10.1016/j.prro.2024.11.004
Emma C Fields, Walter R Bosch, Kevin V Albuquerque, Rohini Bhatia, Junzo Chino, Brandon Dyer, Beth Erickson, Denise Fabian, David Gaffney, Scott Glaser, Kathy Han, Lara Hathout, I-Chow Hsu, Naresh Jegadeesh, Jenna Kahn, Elizabeth Kidd, Ann Klopp, Eric Leung, Lilie Lin, Michelle Ludwig, Tianjun Ma, Loren Mell, Jyoti Mayadev, Ivy Petersen, Lorraine Portelance, Dominique Rash, Neil Taunk, Akila Viswanathan, Aaron Wolfson, Catheryn Yashar, Anamaria Yeung, Emi Yoshida, Christine M Fisher
Purpose: Accurate target delineation is essential when using intensity-modulated radiotherapy (IMRT) for intact cervical cancer. In 2011, the Radiation Therapy Oncology Group (RTOG) published a consensus guideline using magnetic resonance imaging (MRI). The current project expands on the previous atlas by including computed tomography (CT)-based contours, contours with MRI and positron- emission- tomography (PET) registrations, the addition of common and complex scenarios, and to incorporate information on simulation and treatment planning techniques.
Methods and materials: Twenty-eight experts in gynecologic radiation oncology contoured three cases, first on a non-contrast CT simulation scan, then with registered diagnostic scans. The cases included (1) FIGO IIIC1 with a bulky tumor and vaginal metastasis, (2) FIGO IIB with calcified uterine fibromas, and (3) FIGO IIIC2 with large lymph nodes. The contours on all six datasets (three CT simulations without diagnostic images and three with registered images) were analyzed for consistency of delineation using an expectation-maximization algorithm for simultaneous truth and performance level estimation (STAPLE) with kappa statistics as a measure of agreement. The contours were reviewed, discussed, and edited in a group meeting prior to finalizing.
Results: Contours showed considerable agreement between experts in each of the cases with kappa statistics of 0.67-0.72. For each case, diagnostic PET±MRI was associated with an increase in volume. The largest increase was the CTV primary for Case 2 with a 20% increase in volume and 54% increase in STAPLE estimate volume, which may be due to variance in registration priorities. For the third case, 92.9% increased their CTVs based on the addition of the diagnostic PET scan. The main areas of variance were in determining the superior extent of CTV coverage, coverage of the mesorectum, and simulation and planning protocols.
Conclusions: This study shows the value as well as the challenges of using co-registered diagnostic imaging, with an average increase in volumes when incorporating MRI and PET.
{"title":"Consensus Guidelines for Delineation of Clinical Target Volumes for Intensity-Modulated Radiotherapy for Intact Cervical Cancer: An Update.","authors":"Emma C Fields, Walter R Bosch, Kevin V Albuquerque, Rohini Bhatia, Junzo Chino, Brandon Dyer, Beth Erickson, Denise Fabian, David Gaffney, Scott Glaser, Kathy Han, Lara Hathout, I-Chow Hsu, Naresh Jegadeesh, Jenna Kahn, Elizabeth Kidd, Ann Klopp, Eric Leung, Lilie Lin, Michelle Ludwig, Tianjun Ma, Loren Mell, Jyoti Mayadev, Ivy Petersen, Lorraine Portelance, Dominique Rash, Neil Taunk, Akila Viswanathan, Aaron Wolfson, Catheryn Yashar, Anamaria Yeung, Emi Yoshida, Christine M Fisher","doi":"10.1016/j.prro.2024.11.004","DOIUrl":"10.1016/j.prro.2024.11.004","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate target delineation is essential when using intensity-modulated radiotherapy (IMRT) for intact cervical cancer. In 2011, the Radiation Therapy Oncology Group (RTOG) published a consensus guideline using magnetic resonance imaging (MRI). The current project expands on the previous atlas by including computed tomography (CT)-based contours, contours with MRI and positron- emission- tomography (PET) registrations, the addition of common and complex scenarios, and to incorporate information on simulation and treatment planning techniques.</p><p><strong>Methods and materials: </strong>Twenty-eight experts in gynecologic radiation oncology contoured three cases, first on a non-contrast CT simulation scan, then with registered diagnostic scans. The cases included (1) FIGO IIIC1 with a bulky tumor and vaginal metastasis, (2) FIGO IIB with calcified uterine fibromas, and (3) FIGO IIIC2 with large lymph nodes. The contours on all six datasets (three CT simulations without diagnostic images and three with registered images) were analyzed for consistency of delineation using an expectation-maximization algorithm for simultaneous truth and performance level estimation (STAPLE) with kappa statistics as a measure of agreement. The contours were reviewed, discussed, and edited in a group meeting prior to finalizing.</p><p><strong>Results: </strong>Contours showed considerable agreement between experts in each of the cases with kappa statistics of 0.67-0.72. For each case, diagnostic PET±MRI was associated with an increase in volume. The largest increase was the CTV primary for Case 2 with a 20% increase in volume and 54% increase in STAPLE estimate volume, which may be due to variance in registration priorities. For the third case, 92.9% increased their CTVs based on the addition of the diagnostic PET scan. The main areas of variance were in determining the superior extent of CTV coverage, coverage of the mesorectum, and simulation and planning protocols.</p><p><strong>Conclusions: </strong>This study shows the value as well as the challenges of using co-registered diagnostic imaging, with an average increase in volumes when incorporating MRI and PET.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-12DOI: 10.1016/j.prro.2024.09.016
Alon Witztum, Younes Jourani, Emily Y Hirata, Todd McNutt, Thomas G Purdie, Kristy K Brock, David S Hong, Michelle E Howard, Andra V Krauze, Peter A Balter, Abigail L Stockham, Elizabeth Covington, Ying Xiao, Richard Popple, Charles S Mayo
Purpose/objectives: Tracking patient dose in radiation oncology is challenging due to disparate electronic systems from various vendors. Treatment planning systems (TPS), radiation oncology information systems (ROIS), and electronic health records (EHR) lack uniformity, complicating dose tracking and reporting. To address this, we examined practices in multiple radiation oncology settings and proposed guidelines for current systems.
Material/methods: A survey was conducted among members of various professional groups to understand dose reporting practices in TPS, ROIS, and EHR systems. The aim was to identify consistent components and develop guidelines.
Results: We identified six treatment scenarios where current ROIS defaults fail in accurately representing dose totals. A standardized approach involving three reference point types - Primary Treatment Plan Reference, Dose Check, and Prescription Tracking - was proposed to address these scenarios. Standardizing naming conventions for reference points was also recommended for easier integration with EHRs. The approach requires minimal modifications to existing systems and facilitates easier data transfer and display in EHRs.
Conclusion: Standardizing reference points in commercial TPS and ROIS can bridge infrastructure gaps and improve dose tracking in complex clinical scenarios. This standardization, aligned with AAPM's TG-263, paves the way for continual development of automated, standardized, interoperable tools, enhancing the ease of sharing reference point information.
{"title":"Best practice guidelines for use of reference points in radiation oncology information systems to aggregate longitudinal dosimetric data.","authors":"Alon Witztum, Younes Jourani, Emily Y Hirata, Todd McNutt, Thomas G Purdie, Kristy K Brock, David S Hong, Michelle E Howard, Andra V Krauze, Peter A Balter, Abigail L Stockham, Elizabeth Covington, Ying Xiao, Richard Popple, Charles S Mayo","doi":"10.1016/j.prro.2024.09.016","DOIUrl":"10.1016/j.prro.2024.09.016","url":null,"abstract":"<p><strong>Purpose/objectives: </strong>Tracking patient dose in radiation oncology is challenging due to disparate electronic systems from various vendors. Treatment planning systems (TPS), radiation oncology information systems (ROIS), and electronic health records (EHR) lack uniformity, complicating dose tracking and reporting. To address this, we examined practices in multiple radiation oncology settings and proposed guidelines for current systems.</p><p><strong>Material/methods: </strong>A survey was conducted among members of various professional groups to understand dose reporting practices in TPS, ROIS, and EHR systems. The aim was to identify consistent components and develop guidelines.</p><p><strong>Results: </strong>We identified six treatment scenarios where current ROIS defaults fail in accurately representing dose totals. A standardized approach involving three reference point types - Primary Treatment Plan Reference, Dose Check, and Prescription Tracking - was proposed to address these scenarios. Standardizing naming conventions for reference points was also recommended for easier integration with EHRs. The approach requires minimal modifications to existing systems and facilitates easier data transfer and display in EHRs.</p><p><strong>Conclusion: </strong>Standardizing reference points in commercial TPS and ROIS can bridge infrastructure gaps and improve dose tracking in complex clinical scenarios. This standardization, aligned with AAPM's TG-263, paves the way for continual development of automated, standardized, interoperable tools, enhancing the ease of sharing reference point information.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-11DOI: 10.1016/j.prro.2024.10.013
Christine Bang, Eric Jutkowitz, Eduardo Caputo, Sherry X Yan, Htun Ja Mai, Ghid Kanaan, Tayler Leonard, Taylor Rickard, Thomas Trikalinos, James L Rudolph, Katherine Rieke
Introduction: Heterotopic Ossification (HO) is a benign disorder characterized by ectopic bone formation in soft tissues that can lead to functional loss in patients. We conducted a systematic review of the evidence on the use of Radiation Therapy (RT) for the prevention or treatment of HO.
Methods and materials: Literature searches were conducted using Medline (via PubMed), Embase, and ClinicalTrials.gov to April 1, 2023. Medical Subject Headings (MeSH) and free text terms relevant to HO and radiation therapy were used. In brief, eligible study participants were ≥18 years of age with heterotopic ossification and were treated with low-dose, external RT. Two reviewers selected relevant abstracts and abstracted full text data for analysis. The review followed the PRISMA guidelines.
Results: Ten studies evaluating the effect of RT for either the prevention or treatment of heterotopic ossification met the inclusion for evidence synthesis. Nine RCTs did not clearly report their methods and had medium risk of bias. The studies were conducted between 1988 and 2008 with follow-up ranging on average from three to 59 months post treatment. A total of 1530 participants were analyzed, and 566 were treated with RT following fracture fixation, total hip arthroplasty (THA), or total hip replacement (THR). In pooled data from eight RCTs, there was a non-significant but clinically meaningful reduction in the presence of heterotopic ossification at follow-up for patients who received RT vs. comparators (pooled OR = 0.47, 95% CI [0.19, 1.17]. There was minimal evidence of adverse events.
Conclusion: This systematic review found a clinically, but not statistically, significant benefit of prophylactic RT for HO at follow up. These findings are tempered by a moderate risk of bias. While practice patterns vary, RT for HO prophylaxis, in high-risk patients, may have benefits that outweigh the risks.
导言:异位骨化(HO)是一种良性疾病,其特点是软组织中的异位骨形成,可导致患者功能丧失。我们对使用放射治疗(RT)预防或治疗异位骨化的证据进行了系统性回顾:我们使用 Medline(通过 PubMed)、Embase 和 ClinicalTrials.gov 对截至 2023 年 4 月 1 日的文献进行了检索。使用了与 HO 和放射治疗相关的医学主题词(MeSH)和自由文本词。简而言之,符合条件的研究参与者年龄≥18岁,患有异位骨化并接受过低剂量体外 RT 治疗。两名审稿人选择了相关摘要并摘录了全文数据进行分析。综述遵循 PRISMA 指南:10项评估RT预防或治疗异位骨化效果的研究符合证据综合的要求。9项RCT研究未明确报告其研究方法,存在中等偏倚风险。这些研究在1988年至2008年间进行,平均随访时间从治疗后3个月到59个月不等。共分析了 1530 名参与者,其中 566 人在骨折固定、全髋关节置换术(THA)或全髋关节置换术(THR)后接受了 RT 治疗。汇总八项研究的数据后发现,接受RT治疗的患者在随访时出现异位骨化的几率比接受RT治疗的患者低(汇总OR = 0.47,95% CI [0.19,1.17]),虽然不显著,但却具有临床意义。不良事件的证据极少:本系统综述发现,预防性 RT 对随访的 HO 有临床显著疗效,但无统计学意义。这些研究结果存在一定的偏倚风险。虽然实践模式各不相同,但在高风险患者中预防性 RT 治疗 HO 的益处可能大于风险。
{"title":"Radiation Therapy for Heterotopic Ossification: A Systematic Review.","authors":"Christine Bang, Eric Jutkowitz, Eduardo Caputo, Sherry X Yan, Htun Ja Mai, Ghid Kanaan, Tayler Leonard, Taylor Rickard, Thomas Trikalinos, James L Rudolph, Katherine Rieke","doi":"10.1016/j.prro.2024.10.013","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.013","url":null,"abstract":"<p><strong>Introduction: </strong>Heterotopic Ossification (HO) is a benign disorder characterized by ectopic bone formation in soft tissues that can lead to functional loss in patients. We conducted a systematic review of the evidence on the use of Radiation Therapy (RT) for the prevention or treatment of HO.</p><p><strong>Methods and materials: </strong>Literature searches were conducted using Medline (via PubMed), Embase, and ClinicalTrials.gov to April 1<sub>,</sub> 2023. Medical Subject Headings (MeSH) and free text terms relevant to HO and radiation therapy were used. In brief, eligible study participants were ≥18 years of age with heterotopic ossification and were treated with low-dose, external RT. Two reviewers selected relevant abstracts and abstracted full text data for analysis. The review followed the PRISMA guidelines.</p><p><strong>Results: </strong>Ten studies evaluating the effect of RT for either the prevention or treatment of heterotopic ossification met the inclusion for evidence synthesis. Nine RCTs did not clearly report their methods and had medium risk of bias. The studies were conducted between 1988 and 2008 with follow-up ranging on average from three to 59 months post treatment. A total of 1530 participants were analyzed, and 566 were treated with RT following fracture fixation, total hip arthroplasty (THA), or total hip replacement (THR). In pooled data from eight RCTs, there was a non-significant but clinically meaningful reduction in the presence of heterotopic ossification at follow-up for patients who received RT vs. comparators (pooled OR = 0.47, 95% CI [0.19, 1.17]. There was minimal evidence of adverse events.</p><p><strong>Conclusion: </strong>This systematic review found a clinically, but not statistically, significant benefit of prophylactic RT for HO at follow up. These findings are tempered by a moderate risk of bias. While practice patterns vary, RT for HO prophylaxis, in high-risk patients, may have benefits that outweigh the risks.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-09DOI: 10.1016/j.prro.2024.10.014
Abigail Pepin, Ana Kiess, J Nicholas Lukens, Philipose Mulugeta, Neil K Taunk
Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with 177Lu-PSMA-617. Although 177Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of 177Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.
{"title":"Management of Dry Mouth Toxicity Following <sup>177</sup>Lu-PSMA-617 Radioligand Therapy.","authors":"Abigail Pepin, Ana Kiess, J Nicholas Lukens, Philipose Mulugeta, Neil K Taunk","doi":"10.1016/j.prro.2024.10.014","DOIUrl":"10.1016/j.prro.2024.10.014","url":null,"abstract":"<p><p>Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with <sup>177</sup>Lu-PSMA-617. Although <sup>177</sup>Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of <sup>177</sup>Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.1016/j.prro.2024.10.012
Ji Hyun Hong, Kyu Hye Choi, Ji Sang Kim, Suk Woo Yang, Yeon-Sil Kim
Purpose: Despite the decades of using radiotherapy for Graves' ophthalmopathy, the effects and optimal timing remain unclear. We retrospectively analyzed to evaluate the overall efficacy and response, predictive factors, and the effective timing of radiotherapy by assessing steroid requirement after radiotherapy in patients without prior surgery.
Methods and materials: Between 2008 and 2022, we analyzed 74 patients with Graves' ophthalmopathy who received radiotherapy to both orbits. Concurrent steroid therapy was administered to 51 patients. Symptoms were evaluated using a modified clinical activity score (CAS), defining responders as those with a two or more score improvement in CAS, diplopia, or a significant reduction in exophthalmos asymmetry. Common symptoms included eye swelling (81.1%), and conjunctival edema (81.1%). Diplopia observed in 48 patients (64.9%).
Results: Median follow-up was 44.5 months (range 4.8-169.6). CAS significantly improved in the early-immediate phase, one month after radiotherapy (p<0.001). However, diplopia showed significant improvement at a relatively late phase, 4 months after radiotherapy (p=0.039). Patients treated with steroids concurrently showed a faster response compared to those without steroids. Initiating radiotherapy within 12 months of symptom onset resulted in a shorter duration of steroid use after radiotherapy compared to later initiation (65 vs. 286 days, p=0.011).
Conclusions: Our study suggests an evaluation period of at least four months after radiotherapy regardless of concurrent steroid treatment, recognizing the prolonged improvement timeline for diplopia. Additionally, for reducing steroid use after radiotherapy, our study suggests optimal timing of radiotherapy within 12 months of symptom onset.
{"title":"Radiotherapy for Graves' Ophthalmopathy: When is the Optimal Timing of Treatment and Evaluation.","authors":"Ji Hyun Hong, Kyu Hye Choi, Ji Sang Kim, Suk Woo Yang, Yeon-Sil Kim","doi":"10.1016/j.prro.2024.10.012","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.012","url":null,"abstract":"<p><strong>Purpose: </strong>Despite the decades of using radiotherapy for Graves' ophthalmopathy, the effects and optimal timing remain unclear. We retrospectively analyzed to evaluate the overall efficacy and response, predictive factors, and the effective timing of radiotherapy by assessing steroid requirement after radiotherapy in patients without prior surgery.</p><p><strong>Methods and materials: </strong>Between 2008 and 2022, we analyzed 74 patients with Graves' ophthalmopathy who received radiotherapy to both orbits. Concurrent steroid therapy was administered to 51 patients. Symptoms were evaluated using a modified clinical activity score (CAS), defining responders as those with a two or more score improvement in CAS, diplopia, or a significant reduction in exophthalmos asymmetry. Common symptoms included eye swelling (81.1%), and conjunctival edema (81.1%). Diplopia observed in 48 patients (64.9%).</p><p><strong>Results: </strong>Median follow-up was 44.5 months (range 4.8-169.6). CAS significantly improved in the early-immediate phase, one month after radiotherapy (p<0.001). However, diplopia showed significant improvement at a relatively late phase, 4 months after radiotherapy (p=0.039). Patients treated with steroids concurrently showed a faster response compared to those without steroids. Initiating radiotherapy within 12 months of symptom onset resulted in a shorter duration of steroid use after radiotherapy compared to later initiation (65 vs. 286 days, p=0.011).</p><p><strong>Conclusions: </strong>Our study suggests an evaluation period of at least four months after radiotherapy regardless of concurrent steroid treatment, recognizing the prolonged improvement timeline for diplopia. Additionally, for reducing steroid use after radiotherapy, our study suggests optimal timing of radiotherapy within 12 months of symptom onset.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-07DOI: 10.1016/j.prro.2024.10.011
Jacob Ward, Mark Damante, Seth Wilson, Ahmed Nader Elguindy, Dominic Franceschelli, Vicente de Paulo Martins Coelho, Santino Cua, Daniel Kreatsoulas, Wesley Zoller, Sasha Beyer, Dukagjin Blakaj, Joshua Palmer, Raj Singh, Evan Thomas, Vikram Chakravarthy
Purpose: Carbon fiber-reinforced polyetheretherketone (CFR-PEEK) instrumentation is being used more frequently in the spinal oncology landscape. Better visualization with this material allows for more precise postoperative stereotactic body radiation therapy (SBRT) planning using either computed tomography (CT)-myelography or magnetic resonance imaging (MRI) studies. We compared the dosimetric planning equivalencies and outcomes.
Methods and materials: Thirty-six consecutively treated patients were reviewed who underwent spinal fusion using CFR-PEEK instrumentation for spine metastases followed by postoperative SBRT between January 1, 2022, and April 3, 2023. Patients were divided into 2 cohorts based on the imaging modality, MRI versus CT-myelogram, used for postoperative SBRT planning. Surgical, demographic, postoperative radiation dosimetry, complication, and survival data were collected. Statistical analysis was performed in SPSS (v29.0.1.0).
Results: Eleven patients underwent CT-myelograms, and 25 patients underwent MR-spine imaging for SBRT planning. The median follow-up was 145.5 days (13-530). There were no significant differences between baseline demographic, surgical characteristics, or SBRT dosimetry between the MRI spine and CT-myelogram groups. There was no significant difference between the cohorts for survival (P = .402).
Conclusions: MR scans are an effective choice for postoperative SBRT contouring patients using CFR-PEEK instrumentation for oncologic spinal fusions. Avoidance of CT-myelography reduces the need for an invasive procedure and potential risks including cerebrospinal fluid (CSF) leak, nerve root injury, and increased procedural burden.
{"title":"Use of Magnetic Resonance Imaging for Postoperative Radiation Therapy Planning in Patients with Carbon Fiber-Reinforced Polyetheretherketone Instrumentation.","authors":"Jacob Ward, Mark Damante, Seth Wilson, Ahmed Nader Elguindy, Dominic Franceschelli, Vicente de Paulo Martins Coelho, Santino Cua, Daniel Kreatsoulas, Wesley Zoller, Sasha Beyer, Dukagjin Blakaj, Joshua Palmer, Raj Singh, Evan Thomas, Vikram Chakravarthy","doi":"10.1016/j.prro.2024.10.011","DOIUrl":"10.1016/j.prro.2024.10.011","url":null,"abstract":"<p><strong>Purpose: </strong>Carbon fiber-reinforced polyetheretherketone (CFR-PEEK) instrumentation is being used more frequently in the spinal oncology landscape. Better visualization with this material allows for more precise postoperative stereotactic body radiation therapy (SBRT) planning using either computed tomography (CT)-myelography or magnetic resonance imaging (MRI) studies. We compared the dosimetric planning equivalencies and outcomes.</p><p><strong>Methods and materials: </strong>Thirty-six consecutively treated patients were reviewed who underwent spinal fusion using CFR-PEEK instrumentation for spine metastases followed by postoperative SBRT between January 1, 2022, and April 3, 2023. Patients were divided into 2 cohorts based on the imaging modality, MRI versus CT-myelogram, used for postoperative SBRT planning. Surgical, demographic, postoperative radiation dosimetry, complication, and survival data were collected. Statistical analysis was performed in SPSS (v29.0.1.0).</p><p><strong>Results: </strong>Eleven patients underwent CT-myelograms, and 25 patients underwent MR-spine imaging for SBRT planning. The median follow-up was 145.5 days (13-530). There were no significant differences between baseline demographic, surgical characteristics, or SBRT dosimetry between the MRI spine and CT-myelogram groups. There was no significant difference between the cohorts for survival (P = .402).</p><p><strong>Conclusions: </strong>MR scans are an effective choice for postoperative SBRT contouring patients using CFR-PEEK instrumentation for oncologic spinal fusions. Avoidance of CT-myelography reduces the need for an invasive procedure and potential risks including cerebrospinal fluid (CSF) leak, nerve root injury, and increased procedural burden.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-06DOI: 10.1016/j.prro.2024.10.010
Laura L Dover, Christopher Abraham, Adam J Kole, Ashley Weiner
Low-dose chest CT imaging for lung cancer screening is revealing increasing numbers of radiographic early-stage lung cancers. This topic discussion describes when a clinical scenario merits radiotherapy without a histologic diagnosis, with an emphasis on pragmatic algorithms in settings without readily-available advanced biopsy techniques.
{"title":"Appropriateness criteria for radiotherapy in the setting of presumed early-stage lung cancer.","authors":"Laura L Dover, Christopher Abraham, Adam J Kole, Ashley Weiner","doi":"10.1016/j.prro.2024.10.010","DOIUrl":"https://doi.org/10.1016/j.prro.2024.10.010","url":null,"abstract":"<p><p>Low-dose chest CT imaging for lung cancer screening is revealing increasing numbers of radiographic early-stage lung cancers. This topic discussion describes when a clinical scenario merits radiotherapy without a histologic diagnosis, with an emphasis on pragmatic algorithms in settings without readily-available advanced biopsy techniques.</p>","PeriodicalId":54245,"journal":{"name":"Practical Radiation Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142632520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}